# A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants

> **NCT02578550** · PHASE1 · COMPLETED · sponsor: **Janssen Sciences Ireland UC** · enrollment: 126 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC)
- **DRUG:** Emtricitabine/tenofovir alafenamide FDC
- **DRUG:** Darunavir
- **DRUG:** Cobicistat

## Key facts

- **NCT ID:** NCT02578550
- **Lead sponsor:** Janssen Sciences Ireland UC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02578550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02578550, "A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02578550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*